Aligos Therapeutics Inc ALGS

US Biotechnology

$5.51 ▼ -0.72% ($-0.04)

🎈 Low Float 🎢 High Beta

Open $5.70

Prev Close $5.55

Day Range $5.47 – $5.77

52W Range $3.98 – $13.69

Market Cap $34.66M

Beta 2.48

EPS (TTM) $-7.31

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-10-16
Shares Out.	6,190,000
Website	aligos.com/ ↗
Phone	13026587581
Employees	82
Revenue	$27.8M
Gross Profit	$27.8M
Net Income	-$1.5M
Free Cash Flow	-$94.5M
Total Assets	$66.3M
Total Liabilities	$34.4M
Equity	$31.9M

About Aligos Therapeutics Inc

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Aligos Therapeutics Inc is a publicly traded company under the ticker symbol ALGS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.